Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study.
Journal
Blood cancer journal
ISSN: 2044-5385
Titre abrégé: Blood Cancer J
Pays: United States
ID NLM: 101568469
Informations de publication
Date de publication:
19 07 2022
19 07 2022
Historique:
received:
02
03
2022
accepted:
28
06
2022
revised:
17
06
2022
entrez:
19
7
2022
pubmed:
20
7
2022
medline:
22
7
2022
Statut:
epublish
Résumé
Hairy cell leukemia (HCL) is a rare lymphoproliferative disease with an excellent prognosis after treatment with cladribine (2CDA), although relapse may occur during follow-up. The aim of the study is to review the efficacy, safety, long-term remission rate, and overall survival (OS) in those patients who received 2CDA as first-line treatment. We retrospectively reviewed data of HCL patients treated with 2CDA between March 1991 and May 2019 at 18 Italian Hematological centers: 513 patients were evaluable for study purpose. The median age was 54 years (range 24-88) and ECOG was 0 in 84.9% of cases. A total of 330 (64.3%) patients received 2CDA intravenously and 183 (35.7%) subcutaneously. ORR was 91.8%: CR was obtained in 335 patients (65.3%), PR in 96 (18.7%), and hematological response in 40 (7.8%) patients; in 42 (8.2%) no response was observed. Hemoglobin value (p = 0.044), frequency of circulating hairy cells (p = 0.039), recovery of absolute neutrophil count (p = 0.006), and normalization of spleen (p ≤ 0.001) were associated with CR compared to PR in univariable analysis. At a median follow-up of 6.83 years (range 0.04-28.52), the median time to relapse was 12.2 years. A significant difference in duration of response was identified between patients that obtained a CR and PR (19.4 years versus 4.8 years, p < 0.0001). Non-hematological grade 3 or higher early toxicity was reported in 103 (20.1%) patients. Median OS was not reached: 95.3%, 92.4%, and 81.8% of patients were estimated to be alive at 5, 10, and 15 years, respectively. Forty-nine patients died (9.5%), following an infection in 14 cases (2.7%), natural causes in 14 (2.7%), cardiovascular events in 13 (2.5%), a second neoplasm in 6 (1.2%), and progression of HCL in 2 cases (0.4%). Following treatment of HCL with 2CDA, 80% of patients are estimated to be alive 15 years after diagnosis.
Identifiants
pubmed: 35853850
doi: 10.1038/s41408-022-00702-9
pii: 10.1038/s41408-022-00702-9
pmc: PMC9296486
doi:
Substances chimiques
Antineoplastic Agents
0
Cladribine
47M74X9YT5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
109Informations de copyright
© 2022. The Author(s).
Références
Am J Hematol. 2019 Dec;94(12):1413-1422
pubmed: 31591741
Blood. 2017 Feb 2;129(5):553-560
pubmed: 27903528
Blood Adv. 2020 Aug 11;4(15):3699-3707
pubmed: 32777066
Leuk Lymphoma. 2009 Oct;50 Suppl 1:12-7
pubmed: 19814692
N Engl J Med. 2011 Jun 16;364(24):2305-15
pubmed: 21663470
J Clin Oncol. 1998 Sep;16(9):3007-15
pubmed: 9738569
Cancer. 2010 Oct 15;116(20):4788-92
pubmed: 20597132
J Hematol Oncol. 2021 Feb 24;14(1):35
pubmed: 33627164
Blood. 2009 Nov 19;114(21):4696-702
pubmed: 19667403
Blood. 2021 Jun 24;137(25):3473-3483
pubmed: 33754642
Ann Oncol. 2002 Oct;13(10):1641-9
pubmed: 12377655
Blood. 2010 Mar 11;115(10):1893-6
pubmed: 20056789
Hematol Oncol. 2019 Jun;37 Suppl 1:30-37
pubmed: 31187521
J Clin Oncol. 1995 Apr;13(4):989-95
pubmed: 7707128
N Engl J Med. 1990 Apr 19;322(16):1117-21
pubmed: 1969613
Blood Cancer J. 2020 May 27;10(5):62
pubmed: 32461544
N Engl J Med. 2015 Oct 29;373(18):1733-47
pubmed: 26352686
J Clin Oncol. 2020 May 10;38(14):1527-1538
pubmed: 32109194
Blood. 2014 Jan 9;123(2):177-83
pubmed: 24192579
Blood. 1998 Sep 15;92(6):1918-26
pubmed: 9731048
N Engl J Med. 2021 May 13;384(19):1810-1823
pubmed: 33979489
J Clin Med. 2021 Jun 25;10(13):
pubmed: 34202156
J Clin Oncol. 2003 Mar 1;21(5):891-6
pubmed: 12610190
Blood. 2007 May 1;109(9):3672-5
pubmed: 17209059
Br J Haematol. 2009 Jun;145(6):733-40
pubmed: 19344416
Leuk Lymphoma. 2011 Jun;52 Suppl 2:50-2
pubmed: 21504285
Blood. 2012 Jan 5;119(1):192-5
pubmed: 22028477
Leukemia. 2021 Nov;35(11):3314-3318
pubmed: 33731847